Abstract

Background & Aim: The testing for HBcAb is done by different blood centres to ensure the blood safety for transfusion. However, In India, HBcAb is not compulsory test as per Drugs and Cosmetics Act, 1940. Introduction of ID-NAT (Nucleic Acid Testing) for detection of HBV DNA have proven to be of great success but on the contrary increase the cost of blood transfusion. Therefore, the present study was undertaken to find the possibility of obviating the need of screening of HBcAb with existing ID-NAT, so as to optimize the resource utilization. Materials & Methods: Donor blood samples between October 2008 and April 2010 covering 8221 samples were collected and tested simultaneously for Anti-HBc and HBsAg ELISA and ID-NAT tests. Results: Nearly 7% (581) were reactive for HBV marker. Further the samples reactive to serological markers HBsAg & HBcAb (Total), were compared with ID-NAT. Of all the samples reactive for HBV, 7.6% was reactive by ID- NAT. About 2.07% of solitary HBcAb reactive samples were reactive by ID-NAT (Table 1). However, none of the non- reactive samples was reactive to ID-NAT. Conclusion: Still, HBcAb has a definitive role in ruling out the transmission of HBV among HBsAg non- reactive blood (2.07%; Table 1). On the contrary, not even one sample was NAT reactive and not reactive by CLIA. Screening of blood by Anti- HBcAb didn't enhance the blood safety. In addition, centers that have incorporated NAT testing may not derive any additional benefit as this cannot replace anti-HBc testing, especially in developing country like ours.

Keywords: Hepatitis core antibody · ID-NAT- Individual donor- Nucleic acid Test · HBsAg- Hepatitis B Surface Antigen · TTI- Transfusion Transmitted Infection

References

  1. 1.Zarski JP, Ganem D, and Wright TL (2002) Hepatitis B virus. In Clinical Virology, eds D. D. Richman, R. J. Whitley and F. G. Hayden, pp. 623–57. Washington DC, ASM Press.
  2. 2.Previsani N, Lavanchy D and Siegl, G. (2004) Hepatitis A. In Viral Hepatitis: Molecular Biology, Diagnosis, Epidemiology and Control (Perspectives in Medical Virology, volume 10), ed. I. K. Mushahwar, pp. 1–98. Amsterdam, Elsevier.
  3. 3.Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma: report of seven cases. JAMA 1943; 121: 1332–4.
  4. 4.Morgan HW and Williamson DA. Jaundice following administration of human blood products. BMJ 1943; 1: 750–3.
  5. 5.Narayan S. Microbes and blood transfusion. Indian Journal of Medical Microbiology 2001; 19 (3): 119-126.
  6. 6.Stramer SL. Pooled HBV DNA testing by nucleic acid amplification: implementation or not. Transfusion 2005; 45: 1242–6.
  7. 7.Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW et al. Comparative sensitivity of HBV nucleic acid tests and HBsAg assays for detection of acute HBV infections. Transfusion 2003; 43: 788–98.
  8. 8.World Health Organization. Hepatitis B surface antigen assays: operational characteristics (May), Geneva, World Health Organization 2001.
  9. 9.Chaudhuri V, Nanu A, Panda SK, Chand P. Evaluation of serologic screening of blood donors in India reveals a lack of correlation between anti-HBc titer and PCR- amplified HBV DNA.Transfusion 2003; 43: 1442-1448.
  10. 10.Nanu A, Sharma SP, Chatterjee K, Jyoti P. Markers for transfusion-transmissible infections in north Indian voluntary and replacement blood donors: prevalence and trends 1989-1996. Vox Sang 1997; 73: 70-
  11. 11.ORIGINAL ARTICLE MAJMAAH J. HEALTH SCIENCES, 2013 – Vol. 1, No. 2 Evaluation of HbcAb in the presence of ID-NAT, Choudhary RK. 28
  12. 12.Yotsuyanagi H, Yasuda K, Moriya K, Shintani Y, Fujie H, Tsutsumi T et al. Frequent presence of HBV in the sera of HBsAgnegative, anti-HBcpositive blood donors. Transfusion 2001; 41: 1093-1099.
  13. 13.Infectious Disease Testing for Blood Transfusions. NIH Consens Statement 1995 Jan 9-11;13(1):1-29.
  14. 14.Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti- HBc: implications for transfusion transmission and donor screening. Transfusion 2003; 43: 696- 704.
  15. 15.Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942–56.
  16. 16.Busch MP. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfus Clin Biol 2004; 11: 26–32.
  17. 17.Kleinman SH, Strong DM, Tegtmeier GG, Hepatitis B virus (HBV) DNA screening of blood donations in mini-pools with the COBASAmpliScreen HBV test. Transfusion 2005; 45: 1247–57.
  18. 18.Klein HG. Pathogen inactivation technology: cleansing the blood supply. J Intern Med 2005; 257: 224–37.
  19. 19.Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD et al. Photochemical inactivation of virus and bacteria in platelet concentrates by use of a novel psoralen and longwavelength ultraviolet light. Transfusion 1997; 37: 423–
  20. 20.Snyder EL and Dodd RY. (2001) Reducing the risk of blood transfusion. Hematology (Am Soc Hematol Educ Program), 433–42.
  21. 21.Kapoor D, Saxena R, Sood B, Sarin SK. Blood Transfusion practices in India: Results of a national survey. Indian J Gastroenteral 2000; 19: 64-7.
  22. 22.Badur S, Akgun A. Diagnosis of hepatitis B infections and monitoring of treatment. J Clin Virol 2001; 121: 229-37.
  23. 23.Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology 2001; 34:204-6.
  24. 24.Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006; 91: 1-12.
  25. 25.Dreier J, Kroger M, Diekmann J, Gotting C, Kleesiek K. Low-level viraemia of hepatitis B virus in an anti-HBcand anti-HBspositive blood donor. Transfus Med 2004; 14 : 97-103.
  26. 26.Banerjee A, Chandra PK, Datta S, Biswas A, Bhattacharya P, Chakraborty S, et al. Frequency and significance of hepatitis B virus surface gene variant circulating among ‘antiHBc only’ individuals in Eastern India. J Clin Virol 2007; 40 :312-7.
  27. 27.Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E. Antihepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. Transfusion 2007; 47 : 74-9.
  28. 28.Zekri AR, Awlia AA, El Mahalawi H, Ismail EF, Mabrouk GM. Evaluation of blood units with isolated anti HBc for the presence of DNA. Dis Markers 2002; 18: 107-10.
  29. 29.Bhattacharya P, Chandra PK, Datta S, Banerjee A, Chakraborty S, Rajendran K, et al. Significant increase in HBV, HCV, HIV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: exploratory screening reveals high frequency of occult HBV infection. World J Gastroenterol 2007; 13 : 3730-3.
  30. 30.Bre´chot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus: clinically significant or purely occult? Hepatology 2001;34:194-203.
  31. 31.Pawlotsky JM, Bastie A, Hezode C, Lonjon I, Darthuy F, Remire J, Dhumeauz D. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays.J Virol Methods 2000;85:11-21.
  32. 32.Choudhary RK, Singh J, Singh H. Role of anti-HBcore antibody screening by Chemiluminescence in facility with ID-NAT testing; MR international journal of Engineering & Technology 2010; 2(2): 42- 45
  33. 33.Asim M, Ali R, Khan LA, Husain SA, Singla R, Kar P. Significance of anti-HBc screening of blood donors & its association with occult hepatitis B virus infection: Implications for blood transfusion; Indian J Med Res 2010: 312-317.
Majmaah Journal of Health Sciences · eISSN 1658-8223 · Majmaah University · open access